RVL Pharmaceuticals plc revised sales guidance for the fourth quarter of 2022. For the period, the company expects the sales of UPNEEQ to be $12 to $14 million, representing sequential growth of 20% to 40% compared to the third quarter of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | -96.67% |
12/04 | North American Morning Briefing : Big Banks Kick -2- | DJ |
21/03 | North American Morning Briefing : Investors -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
-96.67% | 11.14K | |
-0.28% | 90.59B | |
0.00% | 38.99B | |
-8.52% | 34.09B | |
+64.13% | 26.38B | |
-17.37% | 15.02B | |
-5.99% | 13.17B | |
-10.69% | 11.88B | |
-47.78% | 10.65B | |
+8.09% | 9.25B |
- Stock Market
- Equities
- RVLPQ Stock
- News RVL Pharmaceuticals plc
- RVL Pharmaceuticals plc Revises Sales Guidance for the Fourth Quarter of 2022